A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).

Markus Hecht,Antoniu-Oreste Gostian,Markus Eckstein,Sandra Rutzner,Jens von der Grün,Thomas Illmer,Matthias G. Hautmann,Thomas B. Brunner,Simon Laban,Gunther Klautke,Bálint Tamaskovics,Axel Hinke,Benjamin Frey,Sabine Semrau,Arndt Hartmann,C. Roedel,Wilfried Budach,Udo S. Gaipl,Heinrich Iro,Rainer Fietkau

A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).

2020

6519Background: PD-1/PD-L1 inhibitors are efficient in head and neck squamous cell cancer (HNSCC). Combination with anti-CTLA4 agents may enhance anti-tumor activity compared to anti-PD-1/PD-L1 mon...

Keywords:

Tremelimumab
CD8
Durvalumab
Oncology
Cisplatin/Docetaxel
Internal medicine
single cycle
locally advanced
Pathology
Medicine
INDUCTION TREATMENT

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations